Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Apr 30, 2020

ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases

Apr 22, 2020

ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing

Apr 15, 2020

ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity

Apr 9, 2020

Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates

Apr 7, 2020

ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020

Mar 24, 2020

PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING

Mar 18, 2020

ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results

Feb 26, 2020

ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease

Feb 25, 2020

ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants

Feb 11, 2020

ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference

  • arrow_back
  • 1…
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • …26
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy